<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00805207</url>
  </required_header>
  <id_info>
    <org_study_id>07-0692</org_study_id>
    <secondary_id>NIH P50 HD057796</secondary_id>
    <nct_id>NCT00805207</nct_id>
  </id_info>
  <brief_title>Sex Steroids, Sleep, and Metabolic Dysfunction in Women</brief_title>
  <acronym>SCOR</acronym>
  <official_title>Sex Steroids, Sleep, and Metabolic Dysfunction in Women</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increased plasma triglyceride concentration is a common feature of the metabolic
      abnormalities associated with obesity and a major risk factor for cardiovascular disease.
      Obesity is a major risk factor for two conditions that appear to be increasing in prevalence
      in women: the polycystic ovary syndrome (PCOS) and sleep disordered breathing. PCOS affects
      5-8% of women. Sleep disordered breathing affects up to 10% of women. Obstructive sleep apnea
      (OSA) is the most common cause for sleep disordered breathing and particularly prevalent in
      obese women with PCOS (~50%). Both PCOS and OSA augment the increase in plasma triglyceride
      (TG) concentration associated with obesity, and the effects of PCOS and OSA on plasma TG
      concentration appear to be additive. The mechanisms responsible for the adverse effects on
      plasma TG metabolism are not known. The primary goal of this project, therefore, is to
      determine the mechanisms responsible for the increase in plasma TG concentration in obese
      women with PCOS and OSA. It is our general hypothesis that alterations in the hormonal milieu
      that are characteristic of these two conditions are, at least in part, responsible for the
      increase in plasma TG concentration in obese women with the conditions. Furthermore, we
      hypothesize that the hormonal aberrations characteristic of the two conditions are
      particularly harmful to obese, compared with lean, women.

      The effects of PCOS on skeletal muscle protein metabolism are also not known. However, sex
      hormones are thought to be important regulators of muscle protein turnover suggesting that
      muscle protein metabolism is likely to be affected by PCOS. We will examine this by
      determining the effect of individual sex hormones on muscle protein metabolism and
      hypothesize that testosterone administration will stimulate muscle protein metabolism while
      estrogen and progesterone administration will inhibit muscle protein metabolism.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">March 2013</completion_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate</measure>
    <time_frame>Before and at the end of interventions</time_frame>
    <description>VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The hepatic (liver) secretion rates of VLDL-TG was calculated by multiplying the fractional turnover rates of VLDL-TG by the of VLDL-TG concentration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentration</measure>
    <time_frame>Before and at the end of the interventions</time_frame>
    <description>VLDL was isolated from plasma by ultracentrifugation with VLDL-TG concentration measured by using a colorimetric enzymatic kit (Sigma-Aldrich, St. Louis, MO).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-TG Plasma Clearance Rate (Means)</measure>
    <time_frame>Before and at the end of the interventions</time_frame>
    <description>VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The plasma clearance rate of VLDL-TG was calculated by dividing the VLDL-TG secretion rate by the VLDL-TG concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>VLDL-TG Plasma Clearance Rate (Medians)</measure>
    <time_frame>Before and at the end of the interventions</time_frame>
    <description>VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The plasma clearance rate of VLDL-TG was calculated by dividing the VLDL-TG secretion rate by the VLDL-TG concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Basal, Postabsorptive Fractional Synthesis Rates of Muscle Protein Synthesis</measure>
    <time_frame>Before and at the end of the intervention</time_frame>
    <description>The fractional synthesis rate (FSR) of muscle protein synthesis was determined by assessing the incorporation of [5,5,5-2H3]leucine into muscle proteins. [5,5,5-2H3]leucine was infused for 5 hours with muscle biopsies obtained from the vastus lateralis muscle in the thigh 2 and 5 hours. The leucine tracer-to-tracee ratio (TTR) in muscle protein and the muscle free leucine pool was determined by gas chromatography-mass spectrometry (GCMS) and the FSR of muscle proteins calculated using a standard precursor-product model.
The FSR was calculated as %/h, which reflects the percent of all proteins in the muscle that were synthesized (made) per hour.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Polycystic Ovary Syndrome (PCOS)</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Progesterone - PCOS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women with obesity and polycystic ovary syndrome</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone - premenopausal women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy premenopausal women.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continuous positive airway pressure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Women and men with obesity and obstructive sleep apnea</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucocorticoid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lean and obese healthy women, and obese men</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Estrogen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postmenopausal women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Postmenopausal women - tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control - baseline testing only</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Healthy men and women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Progesterone - Postmenopausal women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postmenopausal women</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Testosterone - Postmenopausal women</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Postmenopausal women</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progesterone</intervention_name>
    <description>Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
    <arm_group_label>Progesterone - PCOS</arm_group_label>
    <arm_group_label>Progesterone - Postmenopausal women</arm_group_label>
    <other_name>Endometrin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone</intervention_name>
    <description>Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
    <arm_group_label>Testosterone - Postmenopausal women</arm_group_label>
    <arm_group_label>Testosterone - premenopausal women</arm_group_label>
    <other_name>1% AndroGel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>glucocorticoid</intervention_name>
    <description>Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
    <arm_group_label>Glucocorticoid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>continuous positive airway pressure</intervention_name>
    <description>Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.</description>
    <arm_group_label>Continuous positive airway pressure</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Estrogen</intervention_name>
    <description>Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.</description>
    <arm_group_label>Estrogen</arm_group_label>
    <other_name>Estradiol Patch, Mylan Pharmaceuticals Inc.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>No treatment with studies performed 31 to 72 days apart</description>
    <arm_group_label>control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women aged 18-75 years and men 45-75 years

          -  Healthy lean, overweight and obese women (BMI 18-40 kg/m2) and obese men (BMI 30-40
             kg/m2)

          -  Obese women (BMI 30-40 kg/m2) with OSA or PCOS

        Exclusion Criteria:

          -  Pregnant, lactating, peri- or postmenopausal women will be excluded from the study
             because of potential confounding influences of these factors and potential ethical
             concerns (pregnant women)

          -  Women taking medications known to affect substrate metabolism and those with evidence
             of significant organ dysfunction (e.g. impaired glucose tolerance, diabetes mellitus,
             liver disease, hypo- or hyper-thyroidism) other than PCOS and OSA

          -  Severe hypertriglyceridemia (fasting plasma TG concentration &gt;400 mg/dl)

          -  Subjects with OSA who have an apnea-hypopnea index (AHI) score &gt;30 (the total number
             of obstructive events divided by the total hours of sleep) will be excluded and
             instructed to seek medical care
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bettina Mittendorfer, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Wang X, Magkos F, Patterson BW, Reeds DN, Kampelman J, Mittendorfer B. Low-dose dexamethasone administration for 3 weeks favorably affects plasma HDL concentration and composition but does not affect very low-density lipoprotein kinetics. Eur J Endocrinol. 2012 Aug;167(2):217-23. doi: 10.1530/EJE-12-0180. Epub 2012 May 22.</citation>
    <PMID>22619349</PMID>
  </results_reference>
  <results_reference>
    <citation>Wang X, Smith GI, Patterson BW, Reeds DN, Kampelman J, Magkos F, Mittendorfer B. Testosterone increases the muscle protein synthesis rate but does not affect very-low-density lipoprotein metabolism in obese premenopausal women. Am J Physiol Endocrinol Metab. 2012 Mar 15;302(6):E740-6. doi: 10.1152/ajpendo.00533.2011. Epub 2012 Jan 17.</citation>
    <PMID>22252942</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith GI, Reeds DN, Okunade AL, Patterson BW, Mittendorfer B. Systemic delivery of estradiol, but not testosterone or progesterone, alters very low density lipoprotein-triglyceride kinetics in postmenopausal women. J Clin Endocrinol Metab. 2014 Jul;99(7):E1306-10. doi: 10.1210/jc.2013-4470. Epub 2014 Apr 2.</citation>
    <PMID>24694337</PMID>
  </results_reference>
  <results_reference>
    <citation>Smith GI, Yoshino J, Reeds DN, Bradley D, Burrows RE, Heisey HD, Moseley AC, Mittendorfer B. Testosterone and progesterone, but not estradiol, stimulate muscle protein synthesis in postmenopausal women. J Clin Endocrinol Metab. 2014 Jan;99(1):256-65. doi: 10.1210/jc.2013-2835. Epub 2013 Dec 20.</citation>
    <PMID>24203065</PMID>
  </results_reference>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>December 5, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <results_first_submitted>February 5, 2018</results_first_submitted>
  <results_first_submitted_qc>July 3, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">August 1, 2018</results_first_posted>
  <last_update_submitted>July 3, 2018</last_update_submitted>
  <last_update_submitted_qc>July 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sleep apnea</keyword>
  <keyword>obese</keyword>
  <keyword>Very-low density lipoprotein (VLDL) metabolism</keyword>
  <keyword>isotope tracer</keyword>
  <keyword>women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Estrogens</mesh_term>
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Progesterone</mesh_term>
    <mesh_term>Glucocorticoids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Progesterone - PCOS</title>
          <description>Women with obesity and polycystic ovary syndrome
Progesterone: Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
        </group>
        <group group_id="P2">
          <title>Progesterone - Postmenopausal Women</title>
          <description>Postmenopausal women
Progesterone: Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
        </group>
        <group group_id="P3">
          <title>Testosterone - Premenopausal Women</title>
          <description>Healthy premenopausal women
Testosterone: Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
        </group>
        <group group_id="P4">
          <title>Testosterone - Postmenopausal Women</title>
          <description>Postmenopausal women
Testosterone: Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
        </group>
        <group group_id="P5">
          <title>Continuous Positive Airway Pressure</title>
          <description>Obese women and men with obstructive sleep apnea
continuous positive airway pressure: Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks</description>
        </group>
        <group group_id="P6">
          <title>Glucocorticoid</title>
          <description>Lean and obese healthy women, and obese men
glucocorticoid: Dexamethasone 0.013 mg/kg fat-free mass daily, 21 days</description>
        </group>
        <group group_id="P7">
          <title>Estrogen</title>
          <description>Postmenopausal women
Estrogens: Estrogen treatment (100 ug Estradiol daily) administered 14 days followed by 14 days without treatment. Repeat this cycle 3 times.</description>
        </group>
        <group group_id="P8">
          <title>Control</title>
          <description>Postmenopausal women - tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits</description>
        </group>
        <group group_id="P9">
          <title>Control - Baseline Testing Only</title>
          <description>Baseline testing only in pre- and postmenopausal women</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="12"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="11"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="9"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Testosterone - Premenopausal Women</title>
          <description>Healthy, premenopausal women
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention</description>
        </group>
        <group group_id="B2">
          <title>Testosterone - Postmenopausal Women</title>
          <description>Postmenopausal women
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
        </group>
        <group group_id="B3">
          <title>Progesterone - PCOS</title>
          <description>Women with obesity and polycystic ovary syndrome
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
        </group>
        <group group_id="B4">
          <title>Progesterone - Postmenopausal Women</title>
          <description>Postmenopausal women
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
        </group>
        <group group_id="B5">
          <title>Continuous Positive Airway Pressure</title>
          <description>Women and men with obesity and obstructive sleep apnea
continuous positive airway pressure: Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks</description>
        </group>
        <group group_id="B6">
          <title>Glucocorticoid</title>
          <description>Lean and obese healthy women, and obese men
Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
        </group>
        <group group_id="B7">
          <title>Estrogen</title>
          <description>Postmenopausal women
Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.</description>
        </group>
        <group group_id="B8">
          <title>Control</title>
          <description>Postmenopausal women
Tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits</description>
        </group>
        <group group_id="B9">
          <title>Control - Baseline Testing Only</title>
          <description>Healthy men and women
Baseline testing only</description>
        </group>
        <group group_id="B10">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="1"/>
            <count group_id="B4" value="9"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="12"/>
            <count group_id="B7" value="6"/>
            <count group_id="B8" value="6"/>
            <count group_id="B9" value="6"/>
            <count group_id="B10" value="61"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35" spread="8"/>
                    <measurement group_id="B2" value="57" spread="6"/>
                    <measurement group_id="B3" value="22" spread="0"/>
                    <measurement group_id="B4" value="63" spread="7"/>
                    <measurement group_id="B5" value="62" spread="12"/>
                    <measurement group_id="B6" value="38" spread="13"/>
                    <measurement group_id="B7" value="59" spread="10"/>
                    <measurement group_id="B8" value="64" spread="6"/>
                    <measurement group_id="B9" value="41" spread="15"/>
                    <measurement group_id="B10" value="49" spread="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="9"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="8"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="12"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="6"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate</title>
        <description>VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The hepatic (liver) secretion rates of VLDL-TG was calculated by multiplying the fractional turnover rates of VLDL-TG by the of VLDL-TG concentration.</description>
        <time_frame>Before and at the end of interventions</time_frame>
        <population>Not included in final analysis:
Withdrawn/withdrew= Testosterone premenopausal women x 1; Progesterone postmenopausal women x 2; Glucocorticoid x 3.
VLDL-TG fractional turnover rate was 3 Standard Deviations from the mean = Testosterone - premenopausal women x 1.
Undetectable VLDL-TG concentration = Progesterone - Postmenopausal women x 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone - Premenopausal Women</title>
            <description>Healthy, premenopausal women.
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone - Postmenopausal Women</title>
            <description>Postmenopausal women
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O3">
            <title>Progesterone - PCOS</title>
            <description>Women with obesity and polycystic ovary syndrome
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
          </group>
          <group group_id="O4">
            <title>Progesterone - Postmenopausal Women</title>
            <description>Postmenopausal women
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
          </group>
          <group group_id="O5">
            <title>Continuous Positive Airway Pressure</title>
            <description>Women and men with obesity and obstructive sleep apnea
Continuous positive airway pressure: Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks</description>
          </group>
          <group group_id="O6">
            <title>Glucocorticoid</title>
            <description>Lean and obese healthy women, and obese men
Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O7">
            <title>Estrogen</title>
            <description>Postmenopausal women
Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.</description>
          </group>
          <group group_id="O8">
            <title>Control</title>
            <description>Postmenopausal women
Tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits</description>
          </group>
          <group group_id="O9">
            <title>Control - Baseline Testing Only</title>
            <description>Healthy men and women
Baseline testing only</description>
          </group>
        </group_list>
        <measure>
          <title>Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Secretion Rate</title>
          <description>VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The hepatic (liver) secretion rates of VLDL-TG was calculated by multiplying the fractional turnover rates of VLDL-TG by the of VLDL-TG concentration.</description>
          <population>Not included in final analysis:
Withdrawn/withdrew= Testosterone premenopausal women x 1; Progesterone postmenopausal women x 2; Glucocorticoid x 3.
VLDL-TG fractional turnover rate was 3 Standard Deviations from the mean = Testosterone - premenopausal women x 1.
Undetectable VLDL-TG concentration = Progesterone - Postmenopausal women x 1.</population>
          <units>umol/min/L plasma</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.13" spread="2.11"/>
                    <measurement group_id="O2" value="2.03" spread="0.35"/>
                    <measurement group_id="O3" value="4.66"/>
                    <measurement group_id="O4" value="3.36" spread="1.65"/>
                    <measurement group_id="O5" value="2.87" spread="0.03"/>
                    <measurement group_id="O6" value="3.80" spread="1.52"/>
                    <measurement group_id="O7" value="2.87" spread="0.86"/>
                    <measurement group_id="O8" value="2.47" spread="0.85"/>
                    <measurement group_id="O9" value="3.53" spread="2.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" spread="1.58"/>
                    <measurement group_id="O2" value="2.11" spread="0.80"/>
                    <measurement group_id="O3" value="7.77"/>
                    <measurement group_id="O4" value="3.24" spread="1.55"/>
                    <measurement group_id="O5" value="3.94" spread="0.42"/>
                    <measurement group_id="O6" value="3.42" spread="2.01"/>
                    <measurement group_id="O7" value="2.94" spread="1.40"/>
                    <measurement group_id="O8" value="2.57" spread="1.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.70</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <p_value_desc>P-value is the main effect of treatment (i.e., Before vs. After) from ANOVA</p_value_desc>
            <method>ANOVA</method>
            <method_desc>VLDL-TG secretion rates were skewed and log transformed prior to performing ANOVA</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <p_value_desc>P-value is the main effect of group (i.e., Testosterone, Progesterone, Estrogen and Control) from ANOVA</p_value_desc>
            <method>ANOVA</method>
            <method_desc>VLDL-TG secretion rates were skewed and log transformed prior to performing ANOVA</method_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.98</p_value>
            <p_value_desc>P value is the group by treatment interaction from the ANOVA</p_value_desc>
            <method>ANOVA</method>
            <method_desc>VLDL-TG secretion rates were skewed and log transformed prior to performing ANOVA</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentration</title>
        <description>VLDL was isolated from plasma by ultracentrifugation with VLDL-TG concentration measured by using a colorimetric enzymatic kit (Sigma-Aldrich, St. Louis, MO).</description>
        <time_frame>Before and at the end of the interventions</time_frame>
        <population>Not included in final analysis:
Withdrawn/withdrew = Testosterone premenopausal women x 1; Progesterone postmenopausal women x 2; Glucocorticoid x 3.
VLDL-TG fractional turnover rate was 3 Standard Deviations from the mean = Testosterone - premenopausal women x 1.
Undetectable VLDL-TG concentration = Progesterone - Postmenopausal women x 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone - Premenopausal Women</title>
            <description>Healthy, premenopausal women.
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone - Postmenopausal Women</title>
            <description>Postmenopausal women
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O3">
            <title>Progesterone - PCOS</title>
            <description>Women with obesity and polycystic ovary syndrome
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
          </group>
          <group group_id="O4">
            <title>Progesterone - Postmenopausal Women</title>
            <description>Postmenopausal women
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
          </group>
          <group group_id="O5">
            <title>Continuous Positive Airway Pressure</title>
            <description>Women and men with obesity and obstructive sleep apnea
Continuous positive airway pressure: Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks</description>
          </group>
          <group group_id="O6">
            <title>Glucocorticoid</title>
            <description>Lean and obese healthy women, and obese men
Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O7">
            <title>Estrogen</title>
            <description>Postmenopausal women
Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.</description>
          </group>
          <group group_id="O8">
            <title>Control</title>
            <description>Postmenopausal women
Tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits</description>
          </group>
          <group group_id="O9">
            <title>Control - Baseline Testing Only</title>
            <description>Healthy men and women
Baseline testing only</description>
          </group>
        </group_list>
        <measure>
          <title>Very-Low Density Lipoprotein-Triglyceride (VLDL-TG) Concentration</title>
          <description>VLDL was isolated from plasma by ultracentrifugation with VLDL-TG concentration measured by using a colorimetric enzymatic kit (Sigma-Aldrich, St. Louis, MO).</description>
          <population>Not included in final analysis:
Withdrawn/withdrew = Testosterone premenopausal women x 1; Progesterone postmenopausal women x 2; Glucocorticoid x 3.
VLDL-TG fractional turnover rate was 3 Standard Deviations from the mean = Testosterone - premenopausal women x 1.
Undetectable VLDL-TG concentration = Progesterone - Postmenopausal women x 1.</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.29"/>
                    <measurement group_id="O2" value="0.18" spread="0.09"/>
                    <measurement group_id="O3" value="0.75"/>
                    <measurement group_id="O4" value="0.42" spread="0.18"/>
                    <measurement group_id="O5" value="0.50" spread="0.06"/>
                    <measurement group_id="O6" value="0.35" spread="0.16"/>
                    <measurement group_id="O7" value="0.50" spread="0.28"/>
                    <measurement group_id="O8" value="0.30" spread="0.15"/>
                    <measurement group_id="O9" value="0.32" spread="0.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.50"/>
                    <measurement group_id="O2" value="0.18" spread="0.10"/>
                    <measurement group_id="O3" value="1.03"/>
                    <measurement group_id="O4" value="0.44" spread="0.36"/>
                    <measurement group_id="O5" value="0.64" spread="0.18"/>
                    <measurement group_id="O6" value="0.33" spread="0.22"/>
                    <measurement group_id="O7" value="0.35" spread="0.22"/>
                    <measurement group_id="O8" value="0.28" spread="0.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.31</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VLDL-TG Plasma Clearance Rate (Means)</title>
        <description>VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The plasma clearance rate of VLDL-TG was calculated by dividing the VLDL-TG secretion rate by the VLDL-TG concentration.</description>
        <time_frame>Before and at the end of the interventions</time_frame>
        <population>Not included in final analysis:
Withdrawn/withdrew= Testosterone premenopausal women x 1; Progesterone postmenopausal women x 2; Glucocorticoid x 3.
VLDL-TG fractional turnover rate was 3 Standard Deviations from the mean = Testosterone - premenopausal women x 1.
Undetectable VLDL-TG concentration = Progesterone - Postmenopausal women x 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone - Premenopausal Women</title>
            <description>Healthy premenopausal women.
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone - Postmenopausal Women</title>
            <description>Postmenopausal women
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O3">
            <title>Progesterone - PCOS</title>
            <description>Women with obesity and polycystic ovary syndrome
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
          </group>
          <group group_id="O4">
            <title>Progesterone - Postmenopausal Women</title>
            <description>Postmenopausal women
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
          </group>
          <group group_id="O5">
            <title>Continuous Positive Airway Pressure</title>
            <description>Obese women and men with obstructive sleep apnea
continuous positive airway pressure: Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks</description>
          </group>
          <group group_id="O6">
            <title>Glucocorticoid</title>
            <description>Lean and obese healthy women, and obese men
Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O7">
            <title>Estrogen</title>
            <description>Postmenopausal women
Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.</description>
          </group>
          <group group_id="O8">
            <title>Control</title>
            <description>Postmenopausal women
Postmenopausal women - tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits</description>
          </group>
          <group group_id="O9">
            <title>Control - Baseline Testing Only</title>
            <description>Healthy men and women
Baseline testing only</description>
          </group>
        </group_list>
        <measure>
          <title>VLDL-TG Plasma Clearance Rate (Means)</title>
          <description>VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The plasma clearance rate of VLDL-TG was calculated by dividing the VLDL-TG secretion rate by the VLDL-TG concentration.</description>
          <population>Not included in final analysis:
Withdrawn/withdrew= Testosterone premenopausal women x 1; Progesterone postmenopausal women x 2; Glucocorticoid x 3.
VLDL-TG fractional turnover rate was 3 Standard Deviations from the mean = Testosterone - premenopausal women x 1.
Undetectable VLDL-TG concentration = Progesterone - Postmenopausal women x 1.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" spread="16.3"/>
                    <measurement group_id="O2" value="35.1" spread="16.5"/>
                    <measurement group_id="O3" value="20.3"/>
                    <measurement group_id="O4" value="21.2" spread="7.5"/>
                    <measurement group_id="O5" value="19.1" spread="2.7"/>
                    <measurement group_id="O6" value="33.8" spread="11.3"/>
                    <measurement group_id="O7" value="17.4" spread="6.7"/>
                    <measurement group_id="O8" value="22.6" spread="9.0"/>
                    <measurement group_id="O9" value="33.1" spread="13.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.1" spread="51.6"/>
                    <measurement group_id="O2" value="34.5" spread="15.8"/>
                    <measurement group_id="O3" value="24.6"/>
                    <measurement group_id="O4" value="24.9" spread="15.3"/>
                    <measurement group_id="O5" value="20.8" spread="2.8"/>
                    <measurement group_id="O6" value="34.3" spread="21.9"/>
                    <measurement group_id="O7" value="25.1" spread="6.1"/>
                    <measurement group_id="O8" value="23.3" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O6</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.94</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.53</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>VLDL-TG Plasma Clearance Rate (Medians)</title>
        <description>VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The plasma clearance rate of VLDL-TG was calculated by dividing the VLDL-TG secretion rate by the VLDL-TG concentration.</description>
        <time_frame>Before and at the end of the interventions</time_frame>
        <population>Not included in final analysis:
Withdrawn/withdrew= Testosterone premenopausal women x 1; Progesterone postmenopausal women x 2; Glucocorticoid x 3.
VLDL-TG fractional turnover rate was 3 Standard Deviations from the mean = Testosterone - premenopausal women x 1.
Undetectable VLDL-TG concentration = Progesterone - Postmenopausal women x 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone - Premenopausal Women</title>
            <description>Healthy premenopausal women.
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone - Postmenopausal Women</title>
            <description>Postmenopausal women
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O3">
            <title>Progesterone - PCOS</title>
            <description>Women with obesity and polycystic ovary syndrome
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
          </group>
          <group group_id="O4">
            <title>Progesterone - Postmenopausal Women</title>
            <description>Postmenopausal women
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
          </group>
          <group group_id="O5">
            <title>Continuous Positive Airway Pressure</title>
            <description>Obese women and men with obstructive sleep apnea
continuous positive airway pressure: Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks</description>
          </group>
          <group group_id="O6">
            <title>Glucocorticoid</title>
            <description>Lean and obese healthy women, and obese men
Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O7">
            <title>Estrogen</title>
            <description>Postmenopausal women
Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.</description>
          </group>
          <group group_id="O8">
            <title>Control</title>
            <description>Postmenopausal women
Postmenopausal women - tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits</description>
          </group>
          <group group_id="O9">
            <title>Control - Baseline Testing Only</title>
            <description>Healthy men and women
Baseline testing only</description>
          </group>
        </group_list>
        <measure>
          <title>VLDL-TG Plasma Clearance Rate (Medians)</title>
          <description>VLDL was isolated from plasma by ultracentrifugation with the tracer-to-tracee (TTR) of free glycerol in plasma and glycerol in VLDL-TG determined by gas chromatography-mass spectrometry. The fractional turnover rates of VLDL-TG was determined by fitting the glycerol TTR time courses in plasma and in VLDL-TG to a multicompartmental model. The plasma clearance rate of VLDL-TG was calculated by dividing the VLDL-TG secretion rate by the VLDL-TG concentration.</description>
          <population>Not included in final analysis:
Withdrawn/withdrew= Testosterone premenopausal women x 1; Progesterone postmenopausal women x 2; Glucocorticoid x 3.
VLDL-TG fractional turnover rate was 3 Standard Deviations from the mean = Testosterone - premenopausal women x 1.
Undetectable VLDL-TG concentration = Progesterone - Postmenopausal women x 1.</population>
          <units>mL/min</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="9"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" lower_limit="33.8" upper_limit="52.9"/>
                    <measurement group_id="O2" value="32.1" lower_limit="23.1" upper_limit="47.8"/>
                    <measurement group_id="O3" value="20.3"/>
                    <measurement group_id="O4" value="20.8" lower_limit="15.4" upper_limit="25.4"/>
                    <measurement group_id="O5" value="19.1" lower_limit="18.1" upper_limit="20.1"/>
                    <measurement group_id="O6" value="35.8" lower_limit="29.6" upper_limit="40.5"/>
                    <measurement group_id="O7" value="14.4" lower_limit="12.7" upper_limit="20.5"/>
                    <measurement group_id="O8" value="19.6" lower_limit="16.6" upper_limit="26.8"/>
                    <measurement group_id="O9" value="33.4" lower_limit="22.8" upper_limit="43.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="6"/>
                    <count group_id="O9" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.6" lower_limit="19.4" upper_limit="63.5"/>
                    <measurement group_id="O2" value="32.7" lower_limit="24.4" upper_limit="48.1"/>
                    <measurement group_id="O3" value="20.3"/>
                    <measurement group_id="O4" value="22.8" lower_limit="15.7" upper_limit="34.3"/>
                    <measurement group_id="O5" value="20.8" lower_limit="19.9" upper_limit="21.8"/>
                    <measurement group_id="O6" value="27.4" lower_limit="21.5" upper_limit="38.7"/>
                    <measurement group_id="O7" value="24.2" lower_limit="22.0" upper_limit="29.1"/>
                    <measurement group_id="O8" value="22.3" lower_limit="19.0" upper_limit="26.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.80</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Basal, Postabsorptive Fractional Synthesis Rates of Muscle Protein Synthesis</title>
        <description>The fractional synthesis rate (FSR) of muscle protein synthesis was determined by assessing the incorporation of [5,5,5-2H3]leucine into muscle proteins. [5,5,5-2H3]leucine was infused for 5 hours with muscle biopsies obtained from the vastus lateralis muscle in the thigh 2 and 5 hours. The leucine tracer-to-tracee ratio (TTR) in muscle protein and the muscle free leucine pool was determined by gas chromatography-mass spectrometry (GCMS) and the FSR of muscle proteins calculated using a standard precursor-product model.
The FSR was calculated as %/h, which reflects the percent of all proteins in the muscle that were synthesized (made) per hour.</description>
        <time_frame>Before and at the end of the intervention</time_frame>
        <population>Not included in final analysis:
Withdrawn/withdrew = Testosterone premenopausal women x 1; Progesterone postmenopausal women x 2; Glucocorticoid x 3.
Muscle not obtained = Testosterone - premenopausal women x 1; Progesterone postmenopausal women x 1; CPAP x 3; Glucocorticoid x 6; Control - baseline testing only x 6.</population>
        <group_list>
          <group group_id="O1">
            <title>Testosterone - Premenopausal Women</title>
            <description>Healthy premenopausal women.
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O2">
            <title>Testosterone - Postmenopausal Women</title>
            <description>Postmenopausal women
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O3">
            <title>Progesterone - PCOS</title>
            <description>Women with obesity and polycystic ovary syndrome
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
          </group>
          <group group_id="O4">
            <title>Progesterone - Postmenopausal Women</title>
            <description>Postmenopausal women
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
          </group>
          <group group_id="O5">
            <title>Continuous Positive Airway Pressure</title>
            <description>Women and men with obesity and obstructive sleep apnea
continuous positive airway pressure: Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks</description>
          </group>
          <group group_id="O6">
            <title>Glucocorticoid</title>
            <description>Lean and obese healthy women, and obese men
Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
          </group>
          <group group_id="O7">
            <title>Estrogen</title>
            <description>Postmenopausal women
Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.</description>
          </group>
          <group group_id="O8">
            <title>Control</title>
            <description>Postmenopausal women
Tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits</description>
          </group>
          <group group_id="O9">
            <title>Control - Baseline Testing Only</title>
            <description>Healthy men and women
Baseline testing only</description>
          </group>
        </group_list>
        <measure>
          <title>Basal, Postabsorptive Fractional Synthesis Rates of Muscle Protein Synthesis</title>
          <description>The fractional synthesis rate (FSR) of muscle protein synthesis was determined by assessing the incorporation of [5,5,5-2H3]leucine into muscle proteins. [5,5,5-2H3]leucine was infused for 5 hours with muscle biopsies obtained from the vastus lateralis muscle in the thigh 2 and 5 hours. The leucine tracer-to-tracee ratio (TTR) in muscle protein and the muscle free leucine pool was determined by gas chromatography-mass spectrometry (GCMS) and the FSR of muscle proteins calculated using a standard precursor-product model.
The FSR was calculated as %/h, which reflects the percent of all proteins in the muscle that were synthesized (made) per hour.</description>
          <population>Not included in final analysis:
Withdrawn/withdrew = Testosterone premenopausal women x 1; Progesterone postmenopausal women x 2; Glucocorticoid x 3.
Muscle not obtained = Testosterone - premenopausal women x 1; Progesterone postmenopausal women x 1; CPAP x 3; Glucocorticoid x 6; Control - baseline testing only x 6.</population>
          <units>%/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="6"/>
                <count group_id="O8" value="6"/>
                <count group_id="O9" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Before</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.064" spread="0.023"/>
                    <measurement group_id="O2" value="0.056" spread="0.007"/>
                    <measurement group_id="O3" value="0.049"/>
                    <measurement group_id="O4" value="0.054" spread="0.12"/>
                    <measurement group_id="O6" value="0.059" spread="0.007"/>
                    <measurement group_id="O7" value="0.063" spread="0.016"/>
                    <measurement group_id="O8" value="0.064" spread="0.012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>After</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.092" spread="0.024"/>
                    <measurement group_id="O2" value="0.079" spread="0.030"/>
                    <measurement group_id="O3" value="0.083"/>
                    <measurement group_id="O4" value="0.085" spread="0.018"/>
                    <measurement group_id="O6" value="0.061" spread="0.037"/>
                    <measurement group_id="O7" value="0.063" spread="0.026"/>
                    <measurement group_id="O8" value="0.067" spread="0.011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>P-value is the main effect of treatment (i.e., Before vs. After) from ANOVA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.96</p_value>
            <p_value_desc>P-value is the main effect of group (i.e., Testosterone, Progesterone, Estrogen and Control) from ANOVA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>P value is the group by treatment interaction from the ANOVA</p_value_desc>
            <method>ANOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Tukey test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Tukey test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O7</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.10</p_value>
            <method>Tukey test</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O8</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.10</p_value>
            <method>Tukey test</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were monitored over the following periods; Estrogen = 70 days (consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.); Testosterone = 21 days; continuous positive airway pressure = 6 weeks; Dexamethasone = 21 days; Progesterone = 70 days (consisted of 14 days on, 14 days off, 14 days on, 14 days off and a final 14 days on treatment); Control (no treatment) = 31 to 72 days between testing visits.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Testosterone - Premenopausal Women</title>
          <description>Healthy, premenopausal women.
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
        </group>
        <group group_id="E2">
          <title>Testosterone - Postmenopausal Women</title>
          <description>Postmenopausal women
Testosterone gel 1250 ug/d applied transdermally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
        </group>
        <group group_id="E3">
          <title>Progesterone - PCOS</title>
          <description>Women with obesity and polycystic ovary syndrome
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
        </group>
        <group group_id="E4">
          <title>Progesterone - Postmenopausal Women</title>
          <description>Postmenopausal women
Micronized progesterone, 100 mg/d vaginally. The intervention lasts 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment. Testing is performed before and at the end of the 70 day intervention.</description>
        </group>
        <group group_id="E5">
          <title>Continuous Positive Airway Pressure</title>
          <description>Obese women and men with obstructive sleep apnea
Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks. Testing is performed before and at the end of the 6 week intervention.</description>
        </group>
        <group group_id="E6">
          <title>Glucocorticoid</title>
          <description>Lean and obese healthy women, and obese men
Dexamethasone 0.013 mg/kg fat-free mass daily taken orally for a total of 21 days. Testing is performed before and at the end of the 21 day intervention.</description>
        </group>
        <group group_id="E7">
          <title>Estrogen</title>
          <description>Postmenopausal women
Estrogen treatment (100 ug Estradiol daily) administered transdermally by using continuous delivery patches. The intervention lasted 70 days in total and consisted of 14 days on treatment, 14 days off treatment, 14 days on treatment, 14 days off treatment and a final 14 days on treatment.</description>
        </group>
        <group group_id="E8">
          <title>Control</title>
          <description>Postmenopausal women
Tested before and after no treatment. Duration between before and after testing ranged from 31 to 78 days with an average of 46 days between visits</description>
        </group>
        <group group_id="E9">
          <title>Control - Baseline Testing Only</title>
          <description>Healthy men and women
Baseline testing only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <description>One subject in the progesterone group contacted us saying that she was vomiting while not on treatment. Unrelated to treatment was probably due to a viral infection.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>One subject in the progesterone group contacted us saying that she had diarrhea while not on treatment. Unrelated to treatment was probably due to a viral infection.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Shaking</sub_title>
                <description>One subject in the progesterone group contacted us saying that she was shaking violently while not on treatment. Unrelated to treatment was probably due to a viral infection.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Broken ankle</sub_title>
                <description>Subject in Progesterone group broke her ankle while on treatment but unrelated to treatment</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <description>One subject reported that she had a small amount of vaginal discharge while taking estrogen</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <description>One subject reported that she had more acne that usual while taking estrogen</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Itchiness</sub_title>
                <description>On subject reported her ankles were itchy while on progesterone</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gordon Smith, PhD</name_or_title>
      <organization>Washington University in St Louis</organization>
      <phone>314-362-4375</phone>
      <email>gsmith@wustl.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

